Trials / Completed
CompletedNCT01366170
Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
Expression of T Immunoregulatory Proteins in ALK+ Anaplastic Large Cell Lymphoma (ALCL)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 7 (estimated)
- Sponsor
- Children's Oncology Group · Network
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how patients will respond to treatment. PURPOSE: This research trial studies biomarker expression in tissue samples from young patients with anaplastic large cell lymphoma.
Detailed description
OBJECTIVES: * To determine the expression of immunoregulatory proteins including CD4, FOXP3 and CD276 in anaplastic large cell lymphoma (ALCL). * To correlate the expression of these proteins with the levels of anaplastic lymphoma kinase (ALK) autoantibodies in patient of ANHL0131. OUTLINE: Archived tissue microarray samples are analyzed by mass spectrometry and validated by Western blotting, flow cytometry, and IHC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | microarray analysis | |
| GENETIC | protein expression analysis | |
| GENETIC | western blotting | |
| OTHER | flow cytometry | |
| OTHER | immunohistochemistry staining method | |
| OTHER | laboratory biomarker analysis | |
| OTHER | mass spectrometry |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2016-05-01
- First posted
- 2011-06-03
- Last updated
- 2016-05-19
Source: ClinicalTrials.gov record NCT01366170. Inclusion in this directory is not an endorsement.